CHRO: Chromocell Therapeutics Corp. Total Debt to Capital

Chromocell Therapeutics (CHRO) is developing a network for creating non-opioid analgesics, where R&D success and FDA approval drive capital interest. The business faces threats due to a lack of profitability and a reliance on grants for conducting tests. Serving as the primary valuation tool, this price chart, where the indicator is 0.00, complements data on the implementation of eco-friendly filters and energy saving in laboratories.

This ratio measures the proportion of borrowed funds relative to equity, reflecting the degree of financial leverage and the balance sheet's resilience to external shocks. For Chromocell (CHRO), which develops innovative non-opioid analgesics based on sodium channels, the low level of this capital structure metric (total debt-to-equity) confirms the autonomy of its R&D funding and the minimization of credit risks.